Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Hasenclever

Showing results (31-40 of 98) with videos related to

Pageof 10
Sort By:
Plos One|April 3, 2020
Quantitative assessment of interim PET in Hodgkin lymphoma: An evaluation of the qPET method in adult patients in the RAPID trialThomas W Georgi, Lars Kurch, Dirk Hasenclever, et al.
Thrombosis and Haemostasis|May 2, 2008
The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysisMatus Rehak, Jiri Rehak, Marc Müller, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 28, 2025
Feasibility and safety of impact-loading exercise in patients with multiple myeloma-a pilot studyAnne Kollikowski, Marei Schallock, Ruben Ringeisen, et al.
Journal of Cachexia, Sarcopenia and Muscle|August 30, 2019
Prognostic role of body composition parameters in gastric/gastroesophageal junction cancer patients from the EXPAND trialUlrich T Hacker, Dirk Hasenclever, Nicolas Linder, et al.
Plos One|March 28, 2023
Interobserver variability in interim PET assessment in Hodgkin lymphoma-reasons and solutionsThomas W Georgi, Lars Kurch, Dirk Hasenclever, et al.
The Lancet. Oncology|February 2, 2010
Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trialBirte Friedrichs, André Tichelli, Andrea Bacigalupo, et al.
Annals of Hematology|May 12, 2016
Modified BEAM with triple autologous stem cell transplantation for patients with relapsed aggressive non-Hodgkin lymphomaKarin Hohloch, Samira Zeynalova, Björn Chapuy, et al.
Experimental & Translational Stroke Medicine|August 28, 2012
Impact of age on the efficacy of bone marrow mononuclear cell transplantation in experimental strokeDaniel-Christoph Wagner, Mitja Bojko, Myriam Peters, et al.
Cancers|August 12, 2023
Assessing Osteolytic Lesion Size on Sequential CT Scans Is a Reliable Study Endpoint for Bone Remineralization in Newly Diagnosed Multiple MyelomaJan-Peter Grunz, Andreas Steven Kunz, Freerk T Baumann, et al.
The New England Journal of Medicine|June 13, 2003
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's diseaseVolker Diehl, Jeremy Franklin, Michael Pfreundschuh, et al.
Pageof 10

Showing results (31-40 of 98) with videos related to

Sort By:
Pageof 10
Plos One|April 3, 2020
Quantitative assessment of interim PET in Hodgkin lymphoma: An evaluation of the qPET method in adult patients in the RAPID trialThomas W Georgi, Lars Kurch, Dirk Hasenclever, et al.
Thrombosis and Haemostasis|May 2, 2008
The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysisMatus Rehak, Jiri Rehak, Marc Müller, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 28, 2025
Feasibility and safety of impact-loading exercise in patients with multiple myeloma-a pilot studyAnne Kollikowski, Marei Schallock, Ruben Ringeisen, et al.
Journal of Cachexia, Sarcopenia and Muscle|August 30, 2019
Prognostic role of body composition parameters in gastric/gastroesophageal junction cancer patients from the EXPAND trialUlrich T Hacker, Dirk Hasenclever, Nicolas Linder, et al.
Plos One|March 28, 2023
Interobserver variability in interim PET assessment in Hodgkin lymphoma-reasons and solutionsThomas W Georgi, Lars Kurch, Dirk Hasenclever, et al.
The Lancet. Oncology|February 2, 2010
Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trialBirte Friedrichs, André Tichelli, Andrea Bacigalupo, et al.
Annals of Hematology|May 12, 2016
Modified BEAM with triple autologous stem cell transplantation for patients with relapsed aggressive non-Hodgkin lymphomaKarin Hohloch, Samira Zeynalova, Björn Chapuy, et al.
Experimental & Translational Stroke Medicine|August 28, 2012
Impact of age on the efficacy of bone marrow mononuclear cell transplantation in experimental strokeDaniel-Christoph Wagner, Mitja Bojko, Myriam Peters, et al.
Cancers|August 12, 2023
Assessing Osteolytic Lesion Size on Sequential CT Scans Is a Reliable Study Endpoint for Bone Remineralization in Newly Diagnosed Multiple MyelomaJan-Peter Grunz, Andreas Steven Kunz, Freerk T Baumann, et al.
The New England Journal of Medicine|June 13, 2003
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's diseaseVolker Diehl, Jeremy Franklin, Michael Pfreundschuh, et al.
Pageof 10